Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2

Human Gene Therapy

Volumn 10, Issue 7, 1999, Pages 1117-1128

  Machein, Märcia R ^a   Risau, Werner ^b   Plate, Karl H ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DNA TRANSFECTION; FEMALE; GENE THERAPY; GENE TRANSFER; GLIOMA; NONHUMAN; RAT; RETROVIRUS; TUMOR CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALS; BLOTTING, SOUTHERN; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GLIOMA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED F344; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0033134716     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018111     Document Type: Article

References (51)

1. ALON, T., HEMO, I., ITIN, A., PE'ER, J., STONE, J., and KESHET, E. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 10, 1024-1028.
2. ANDERSON, W.F. (1992). Human gene therapy. Science 256, 808-813.
3. AUSUBEL, F.M. (1997). Current Protocols in Molecular Biology, Vol. I. (John Wiley & Sons, New York) chap. 9.1.4.
4. BENJAMIN, L.E., and KESHET, E. (1997). Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels with VEGF withdrawal. Proc. Natl. Acad. Sci. U.S.A. 94, 8761-8766.
5. BLACK, P.M. (1991). Brain tumors. N. Engl. J. Med. 324, 1555-1564.
6. BROWN, L.F., BERSE, B., JACKMAN. R.W., TOGNAZZI, K., MANSEAU, E.J., DVORAK, H.F., and SENGER, D.R. (1993a). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143, 1255-1262.
7. BROWN, L.F., BERSE, B., JACKMAN, R.W., TOGNAZZI, K., MANSEAU, E.J., SENGER, D.R., and DVORAK, H.F. (1993b). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53, 4727-4735.
8. BROWN, L.F., BERSE, B., JACKMAN, R.W., TOGNAZZI, K., GUIDI, A.J., DVORAK, H.F., SENGER, D.R., CONNOLY, J.L., and SCHNITT, S.J. (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26, 86-91.
9. CLAUSS, M., WEICH, H., BREIER, G., KNIES, W., ROCKL, W., WALTENBERGER, J., and RISAU, W. (1996). The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271, 17629-17634.
10. CORNETTA, K., WIEDER, R., and ANDERSON, W.F. (1989). Gene transfer into primates and prospects for gene therapy in humans. Prog. Nucleic Acid Res. Mol. Biol. 36, 311-322.
11. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
12. DAMERT, A., MACHEIN, M., BREIER, G., FUJITA, M.Q., HANAHAN, D., RISAU, W., and PLATE, K.H. (1997). Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 5, 3860-3864.
13. DE VRIES, C., ESCOBEDO, J.A., UENO, H., HOUCK, K., FERRARA, N., and WILLIAMS, L.T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991.
14. FOLKMAN, J. (1995a). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31.
15. FOLKMAN, J. (1995b). Tumor angiogenesis. In The Molecular Basis of Cancer. H. Mendelsoh, P.M. Howley, M.A. Israel, and L.A. Liotta, eds. (W.B. Saunders, Philadelphia) pp. 206-232.
16. FOLKMAN, J., and KLAGSBRUN, M. (1987). Angiogenic factors. Science 235, 442-447.
17. FOLKMAN, J., COLE, P., and ZIMMERMAN, S. (1966). Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal sement. Ann. Surg. 164, 491-502.
18. FONG, G.H., ROSSANT, J., GERTSENSTEIN, M., and BREITMAN, M.L. (1995). Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (London) 375, 66-70.
19. GOLDMAN, C.K., KENDALL, R.L., CABRERA, G., SOROCEANU, L., HEIKE, Y., GILLEPSIE, G.Y., SIEGAL, G.P., MAO, X., HUCKLE, W.R., THOMAS, K.A., and CURIEL, D.T. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis and mortality rate. Proc. Natl. Acad. Sci. U.S.A. 95, 8795-8800.
20. HANAHAN, D. (1997). Signaling vascular morphogenesis and maintanance. Science 277, 48-50.
21. KIEM, H.P., DAROVSKY, B., VON KALLE, C., GOEHLE, S., STEWART, D., GRAHAM, T., HACKMAN, R., APPELBAUM, F.R., DEEG, H.J., MILLER, A.D., STORE, R., and SCHUENING, F.G. (1994). Retrovirus-mediated gene transduction into canine peripheral blood repopulation cells. Blood 83, 1467-1473.
22. KIM, K.J., LI, B., WINER, J., ARMANINI, M., GILLETT, N., PHILLIPS, H.S., and FERRARA, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (London) 362, 841-844.
23. KLAGSBRUN, M., and D'AMORE, P.A. (1991). Regulators of angiogenesis. Annu. Rev. Physiol. 53, 217-239.
24. KONG, H.L., and CRYSTAL, R.G. (1998). Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. 90, 273-286.
25. KONG, H.L., HECHT, D., SONG, W., KOVESDI, I., HACKETT, N.R., YAYON, A., and CRYSTAL, R.G. (1998). Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. 9, 823-833.
26. LIN, P., SANKAR, S., SHAN, S., DEWHIRST, M.W., POLVERINI, P.J., QUINN, T.Q., and PETERS, K.G. (1998). Inhibition of tumor growth by targeting endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 9, 49-58.
27. MATTHEWS, W., JORDAN, C.T., GAVIN, M., JENKINS, N.A., COPELAND, N.G., and LEMISCHKA, I.R. (1991). A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. U.S.A. 88, 9026-9030.
28. MILLAUER, B., WIZIGMANN-VOSS, S., SCHNURCH, H., MARTINEZ, R., MOLLER, N.P., RISAU, W., and ULLRICH, A. (1993). High affinity VEGF binding and development expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846.
29. MILLAUER, B., SHAWVER, L.K., PLATE, K.H., RISAU, W., and ULLRICH, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (London) 367, 576-579.
30. MILLAUER, B., LONGHI, M.P., PLATE, K.H., SHAWVER, L.K., RISAU, W., ULLRICH, A., and STRAWN, L.M. (1996). Dominant-negative inhibition of flk-1 suppresses the growth of many tumors in vivo. Cancer Res. 56, 1615-1620.
31. MILLER, A.D. (1992). Human gene therapy comes of age. Nature (London) 357, 455.
32. MILLER, A.D., and ROSMAN, G.J. (1989). Improved retroviral vectors for gene transfer and expression. BioTechniques 7, 980-990.
33. PLATE, K.H. (1996). Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metastasis Rev. 15, 237-240.
34. PLATE, K.H., and RISAU, W. (1995). Angiogenesis in malignant gliomas. Glia 15, 339-347.
35. PLATE, K.H., BREIER, G., WEICH, H.A., and RISAU, W. (1992). Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature (London) 359, 845-848.
36. PLATE, K.H., BREIER, G., MILLAUER, B., ULLRICH, A., and RISAU, W. (1993). Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53, 5822-5827.
37. PLATE, K.H., BREIER, G., WEICH, H.A., MENNEL, H.D., and RISAU, W. (1994). Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanism. Int. J. Cancer 59, 520-529.
38. PUUMALAINEN, A.M., VAPALAHTI, M., AGRAWAL, R., KOSSILA, M., LAUKKRANEN, J., LEHTOLAINEN, P., VIITA, H., PALJÄRVI, L., VANNINEN, R., and YLÄ-HERTTUALA, S. (1998). β-Galactosidase gene transfer to human malignant glioma in vivo using replicant deficient retrovirus and adenovirus. Hum. Gene Ther. 9, 1769-1774.
39. ROLLINS, S.A., BIRKIS, C.W., SETTER, E., SQUINTO, S.P., and ROTHER, R.P. (1996). Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: Strategies for evading the humoral immune response. Hum. Gene Ther. 7, 619-629.
40. ROSS, G., ERICKSON, R., KNORR, D., MOTULSKY, A.G., PARKMAN, R., SAMULSKI, J., STRAUS, S.E., and SMITH, B.R. (1996). Gene therapy in the United States: A five-year status report. Hum. Gene Ther. 7, 1781-1790.
41. ROTHER, R.P., and SQUINTO, S.P. (1996). The alpha-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable. Cell 86, 185-188.
42. SALEH, M., STACKER, S.A., and WILKS, A.F. (1996). Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 393, 393-401.
43. SENGER, D.R., VAN DE WATER, L., BROWN, L.F., NAGY, J.A., YEO, K.T., YEO, T.K., BERSE, B., JACKMAN, R.W., DVORAK, A.M., and DVORAK, H.F. (1993). Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12, 303-324.
44. SHIBUYA, M., YAMAGUCHI, S., YAMANE, A., IKEDA, T., TOJO, A., MATSUSHIMA, H., and SATO, M. (1990). Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to fms family. Oncogene 5, 519-524.
45. SHWEIKI, D., ITIN, A., SOFFER, D., and KESHET, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (London) 359, 843-845.
46. SKOBE, M., ROCKWELL, P., GOLDSTEIN, N., VOSSELER, S., and FUSENIG, N.E. (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222-1227.
47. STRAWN, L.M., MCMAHON, G., APP, H., SCHRECK, R., KUCHLER, W.R., LONGHI, M.P., HUI, T.H., TANG, C., LEVITZKI, A., GAZIT, A., CHEN, I., KERI, G., ORFI, L., RISAU, W., FLAMME, I., ULLRICH, A., HIRTH, K.P., and SHAWVER, L.K. (1996). Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-3545.
48. SUZUKI, K., HAYASHI, N., MIYAMOTO, Y., YAMAMOTO, M., OHKAWA, K., ITO, Y., SASAKI, Y., YAMAGUCHI, Y., NAKASE, H., NODA, K., ENOMOTO, N., ARAI, K., YAMADA, Y., YOSHIHARA, H., TUJIMURA, T., KAWANO, K., YOSHIKAWA, K., and KAMADA, T. (1996). Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 56, 3004-3009.
49. TEMIN, H.M. (1990). Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Ther. 1, 111-123.
50. TERMAN, B.I., DOUGHER-VERMAZEN, M., CARION, M.E., DIMITROV, D., ARMELLINO, D.C., GOSPODAROWICZ, D., and BOHLEN, P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586.
51. WALTENBERGER, J., CLAESSON-WELSH, L., SIEGBAHN, A., SHIBUYA, M., and HELDIN, C.H. (1994). Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995.